Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
816
Views
0
CrossRef citations to date
0
Altmetric
Coronavirus

Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study

Liping Jina Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China;b National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China;c Furong Laboratory, Changsha, Hunan, China;d Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Yating Diana Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China;b National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China;c Furong Laboratory, Changsha, Hunan, China;d Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Yuming Sunb National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China;c Furong Laboratory, Changsha, Hunan, China;d Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, China;e National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China;f Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Guangtong Denga Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China;b National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China;c Furong Laboratory, Changsha, Hunan, China;d Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, China;e National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Chaofei Hang Department of Burn and Plastic Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCorrespondence[email protected]
View further author information
&
Furong Zenge National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China;h Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCorrespondence[email protected]
View further author information
Article: 2355683 | Received 31 Mar 2024, Accepted 12 May 2024, Published online: 11 Jun 2024

References

  • Zhang XR, Li ZJ, Fu Q, Wang JD, Huang QM, Song WQ, Xu XY, Li ZH, Mao C. The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China. BMC Public Health. 2023;23(1):542. doi:10.1186/s12889-023-15294-7.
  • Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722–33.e11. doi:10.1016/j.cell.2020.06.035.
  • Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–6. doi:10.1016/s1473-3099(21)00127-4.
  • Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, He P, Girsang RT, Vergara H, Akram J. et al. Efficacy and safety of the RBD-dimer–based covid-19 vaccine ZF2001 in adults. N Engl J Med. 2022;386(22):2097–111. doi:10.1056/NEJMoa2202261.
  • An Y, Li S, Jin X, Han JB, Xu K, Xu S, Han Y, Liu C, Zheng T, Liu M. et al. A tandem-repeat dimeric RBD protein-based COVID-19 vaccine zf2001 protects mice and nonhuman primates. Emerg Microbes Infect. 2022;11(1):1058–71. doi:10.1080/22221751.2022.2056524.
  • Author. Approved vaccines. https://covid19.trackvaccines.org/vaccines/approved.
  • Dian Y, Meng Y, Sun Y, Deng G, Zeng F. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J Infect. 2023;87(2):24–7. doi:10.1016/j.jinf.2023.05.012.
  • Zhao D, He Y, Dian Y, Meng Y, Zeng F, Deng G. Elevated troponin levels predict the reduced efficacy of paxlovid in COVID-19 patients. J Infect. 2023;87(2):148–50. doi:10.1016/j.jinf.2023.03.026.
  • Sun Y, Jin L, Dian Y, Shen M, Zeng F, Chen X, Deng G. Oral azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine. 2023;59:101981. doi:10.1016/j.eclinm.2023.101981.
  • Deng G, Li D, Sun Y, Jin L, Zhou Q, Xiao C, Wu Q, Sun H, Dian Y, Zeng F. et al. Real-world effectiveness of azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID-19: A retrospective cohort study. J Med Virol. 2023;95(4):e28756. doi:10.1002/jmv.28756.
  • Zhao D, He Y, Dian Y, Meng Y, Zeng F, Deng G. Elevated troponin levels predict the reduced efficacy of paxlovid in COVID-19 patients. J Infect. 2023;87(2):148–50. doi:10.1016/j.jinf.2023.03.026.
  • Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2022;98(1159):389–94. doi:10.1136/postgradmedj-2021-140654.
  • Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, Sohail MR, Mahmood SF, Ochani R, Hussham Arshad M. et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;29(1):20–36.
  • Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, Li T, Margolick JB, Pawelec G, Leng SX. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. doi:10.1016/j.arr.2020.101205.
  • Bialek S, Boundy E, Bowen V, Chow N, Cohn A, Dowling N, Ellington S, Gierke R, Hall A, MacNeil J. et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–6. doi:10.15585/mmwr.mm6912e2.
  • Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z, Younas S. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833–9. doi:10.1016/j.jiph.2020.07.014.
  • Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, Maor Y, Cohen R, Hussein K, Weinberger M. et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27(11):1652–7. doi:10.1016/j.cmi.2021.06.036.
  • Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, Ceirano A, Espinosa F, Saavedra E, Sanguine V. et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955. doi:10.1371/journal.pone.0241955.
  • Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–36. doi:10.1038/s41577-021-00592-1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.